Skip to content

Tango Therapeutics (TNGX) Gains Momentum on Updated Vopimetostat Data and LOPJLB BUY Signal

2026-10-21 · By Pierre Brunelle · Founder & Research Lead · All notes

TNGXBuyRecovery regimebuy flip

Tango Therapeutics closed at $26.98, up 6.85 % as of 2026‑10‑21 (Wednesday US session), reflecting fresh optimism after the company disclosed new combination‑therapy data and a strong LOPJLB directional signal.

Tango Therapeutics (NASDAQ:TNGX) announced that it will present updated data on its Vopimetostat + RAS(ON) combination at the upcoming European Society for Medical Oncology (ESMO) Congress 2026. The presentation is expected to detail efficacy and safety outcomes from a Phase 1/2 trial that pairs the PRMT5 inhibitor Vopimetostat with a RAS‑activated tumor‑targeting agent. The data could clarify the therapeutic potential of the combination in methylthioadenosine‑phosphorylase‑deficient cancers, a niche where the company’s lead candidate TNG908 is already positioned.

News / Catalysts

These releases collectively underscore a busy pipeline, active investor interest, and ongoing market‑making activity that could support price appreciation.

Fundamentals and Valuation

Tango Therapeutics remains a high‑growth, loss‑making biotech with a market capitalization of $4.55 B. The trailing twelve‑month (TTM) price‑to‑earnings ratio sits at ‑31.74, reflecting the company’s negative earnings per share of ‑$0.87 for the most recent fiscal year (2025). The enterprise‑value‑to‑EBITDA multiple is similarly negative at ‑34.76, driven by operating losses that outweigh earnings before interest, taxes, depreciation, and amortization.

Revenue has surged dramatically over the past five years, climbing from $7.66 M in 2020 to $62.38 M in 2025—a 121.5 % year‑over‑year growth rate reported in the latest fundamentals snapshot. Gross margins have been exceptionally high, averaging ≈98 %, a characteristic of biotech firms with minimal cost of goods sold on research‑stage compounds. However, operating margins are deeply negative at ‑253.4 %, and net margins sit at ‑229.9 %, reflecting substantial R&D and SG&A outlays.

Return metrics underscore the company’s early‑stage status: ROIC is ‑15.45 %, ROE ‑25.74 %, and ROA ‑11.52 %. The balance sheet shows a debt‑to‑equity ratio of 3.12, indicating a leveraged position that is typical for cash‑intensive biotech firms financing clinical programs through a mix of equity and debt. Free‑cash‑flow yield is ‑3.17 %, confirming that cash generation remains negative.

Analyst consensus remains bullish, with an average price target of $45.91 and a “Buy” recommendation across the coverage set. The Altman Z‑score of 55.15 suggests a strong capacity to meet short‑term obligations, albeit the metric is less informative for a pre‑profit biotech.

Valuation snapshot

MetricValue
P/E (TTM)‑31.74
EV/EBITDA‑34.76
P/B3.95
ROE‑25.74 %
ROIC‑15.45 %
Gross margin98.25 %
Operating margin‑253.4 %

Historical financial highlights

The trajectory shows a clear acceleration in top‑line sales, driven largely by licensing and collaboration milestones tied to the PRMT5 program. While profitability remains distant, the revenue expansion and high gross margins provide a foundation for future scale once the pipeline advances into later‑stage trials.

ETF Ownership

Tango Therapeutics is held by six exchange‑traded funds that collectively own roughly 7.05 % of the float. The largest holders are:

ETF (Ticker)Weight
PTH1.89 %
TDNA1.70 %
DWAS1.26 %
XBI0.98 %
CANC0.68 %
FTXH0.54 %

Concentrated institutional ownership can amplify price movements when any of these funds adjust their positions, especially in a low‑float biotech. The presence of sector‑focused ETFs such as XBI (SPDR S&P Biotech ETF) and CANC (Defiance Cancer ETF) also signals that Tango is on the radar of investors targeting oncology‑centric exposure.

LOPJLB Signal Read

The LOPJLB platform flags TNGX with a BUY directional signal and a RECOVERY market‑regime overlay, assigning a composite score of 5. The composite PERF score of 43.90 and FUND quality score of 14.27 place the stock in the Growth Compounder archetype, reflecting strong upside potential amid a broader market rebound.

The signal’s underlying methodology blends price‑action overlays, breadth indicators, and fundamental quality metrics. In the current recovery regime, the EMA bullish crossover (5‑day EMA above 20‑day EMA) and a 100 % stochastic K reading suggest momentum is building.

Readers are encouraged to explore the interactive chart on the Tango Therapeutics page for a visual of the overlays, and to review the full methodology at the LOPJLB research methodology page.

Explore more

The information provided herein is for research purposes only and does not constitute investment advice. All readers should conduct their own due diligence and consult professional advisors before making any investment decisions.

This post is independent quantitative research, not investment advice. LOPJLB signals are model outputs derived from price, volume, and fundamentals. Past backtests do not guarantee future results. Position sizing, execution, and risk management remain the reader's responsibility.

TNGX on today's desk

The note is a snapshot. The stock page and screener carry tonight's re-score, the regime and the backtest behind the call.

OPEN TNGX →OPEN THE SCREENER →